TF expression in cancer can be upregulated by mutations in the tumor suppressor gene TP53 and the proto-oncogene KRAS, which activate the mitogen-activated protein kinase (MAPK) and PI3/AKT signaling pathways, subsequently leading to the upregulation of TF on cancer cells [80]. The gene discussed is TP53; the disease is cancer.